In February 2026, TAP made an equity investment in Wugen to "Support Clinical Development of Sofi-Cel in Relapsed/Refractory T-ALL/T-LBL."
Wugen is a clinical-stage biotechnology company focused on developing next-generation, allogeneic CAR-T cell therapies for cancer. Wugen’s proprietary gene-editing platform is designed to overcome key limitations of first-generation cell therapies, enabling scalable, off-the-shelf treatments with biologics-like cost of goods margins.
Soficabtagene Geleucel (Sofi-cel) is an allogeneic, off-the-shelf, CD7-targeted CAR-T cell therapy engineered to overcome the technological challenges of harnessing CAR-T cells to treat T-cell cancers. Wugen is deploying CRISPR/Cas9 gene editing technology to delete CD7 and the T cell receptor alpha constant (TRAC) genes, thereby preventing CAR-T cell fratricide and mitigating the risk of graft-versus-host disease (GvHD). Sofi-cel is manufactured using healthy donor-derived T cells to eliminate the risk of malignant cell contamination historically observed in the autologous CAR-T setting. Sofi-cel is currently being evaluated in a global pivotal clinical trial for relapsed or refractory T-ALL/T-LBL (NCT06514794).
Sofi-cel has received Regenerative Medicine Advanced Therapy (RMAT), Breakthrough Therapy, Fast Track, Orphan Drug, and Rare Pediatric Disease designations from the U.S. FDA and Priority Medicines (PRIME) Scheme designation in the European Union for the treatment of relapsed or refractory T-ALL/T-LBL. RMAT and PRIME designations provide increased agency support to expedite the development and review of promising therapies for patients in need.
For more information about Wugen visit wugen.com.
Recent News
- July 8, 2026 - announced the successful closing of a $35 million financing round, including participation by TAP and the company introduced its new name, Allotera Therapeutics
- April 2, 2026 - selected for FDA Chemistry, Manufacturing, and Controls Development and Readiness Pilot Program to support manufacturing readiness of Soficabtagene Geleucel
- January 21, 2026 - FDA granted WU-CART-007 Breakthrough Therapy Designation for R/R T-ALL/T-LBL
- December 5, 2025 - presented correlative data and long-term follow-up updates for WU-CART-007 at ASH 2025 Annual Meeting
- August 27, 2025 - secured $115 Million to advance pivotal study of first-in-class allogeneic CAR-T therapy, WU-CART-007
- March 20, 2025 - announced dosing of first patients in pivotal trial of WU-CART-007